# A Clinical Trial of Lurasidone in Treatment of Schizophrenia

> **NCT02002832** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 388 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone tablets
- **DRUG:** Risperidone tablets

## Key facts

- **NCT ID:** NCT02002832
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-04
- **Final completion:** 2015-11
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002832, "A Clinical Trial of Lurasidone in Treatment of Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02002832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*